Currently, Avidity Biosciences Inc. [RNA] is trading at $24.24, up 1.30%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RNA shares have gain 7.93% over the last week, with a monthly amount glided 19.70%, and seem to be holding up well over a long-time horizon.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
On 20, January 2023, Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20, 2023, the Compensation Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,350 shares of its common stock and 6,175 restricted stock units (“RSUs”) to three new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the “2022 Inducement Plan”). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
From an analyst’s perspective:
Avidity Biosciences Inc. [NASDAQ: RNA] stock has seen the most recent analyst activity on July 20, 2022, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $29. Previously, Raymond James started tracking the stock with Strong Buy rating on July 12, 2022, and set its price target to $29. On September 07, 2021, Evercore ISI initiated with a Outperform rating and assigned a price target of $50 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $50 on June 17, 2021. Wells Fargo started tracking with a Overweight rating for this stock on July 07, 2020, and assigned it a price target of $60. In a note dated July 07, 2020, Wells Fargo initiated an Overweight rating.
This stock has fluctuated between a low of $9.83 and a high of $24.32 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $43.29 within the next 12 months. Avidity Biosciences Inc. [NASDAQ: RNA] shares were valued at $24.24 at the most recent close of the market. An investor can expect a potential return of 78.59% based on the average RNA price forecast.
Analyzing the RNA fundamentals
Recent quarter sales for Avidity Biosciences Inc. [NASDAQ:RNA] were 2.48 billion which represents 13.60% growth. Gross Margin for this corporation currently stands at +93.15% with Operating Margin at -1265.83%, Pretax Margin comes in at -1265.38%, and Net Margin reading is -1265.38%.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.63 points at the first support level, and at 23.01 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.78, and for the 2nd resistance point, it is at 25.31.
Avidity Biosciences Inc. [RNA] reported earnings per share of -$0.92 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.75/share, meaning a difference of -$0.17 and a surprise factor of -22.70%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.71 per share as compared to estimates of -$0.8 per share, a difference of $0.09 representing a surprise of 11.30%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Avidity Biosciences Inc. [NASDAQ:RNA] is 9.70. As well, the Quick Ratio is 13.86, while the Cash Ratio is 13.67. Considering the valuation of this stock, the price to sales ratio is 105.59, the price to book ratio is 2.98.
Transactions by insiders
Recent insider trading involved LEVIN ARTHUR A, Chief Scientific Officer, that happened on Jan 12 when 10000.0 shares were sold. Chief Scientific Officer, LEVIN ARTHUR A completed a deal on Dec 29 to sell 40000.0 shares. Meanwhile, President and CEO Boyce Sarah sold 14855.0 shares on Aug 25.